首页 > 最新文献

Arquivos brasileiros de endocrinologia e metabologia最新文献

英文 中文
[Multiple endocrine neoplasia type 2]. [多发性内分泌肿瘤2型]。
Pub Date : 2020-02-10 DOI: 10.32388/0roru0
A. Maia, J. Gross, Márcia Puñales
The term multiple endocrine neoplasia (MEN) was introduced by Steiner et al. in 1968 to describe disorders that include a combination of endocrine tumors. The Wermer syndrome was designed as MEN 1 and the Sipple syndrome as MEN 2. Sizemore et al. (1974) completed that the MEN 2 category included 2 subgroups: patients with medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid disease and a normal appearance (MEN 2A) and other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B). MTC is usually the first tumor diagnosed. The diagnosis of MTC has several implications: disease extent should be evaluated, pheochromocytoma and hyperparathyroidism should be screened and whether the MTC is sporadic or hereditary should be determined by a direct analysis of the RET proto-oncogene. Here, the pathological characteristics, genetic abnormalities, and clinical features of MEN 2 are discussed. The diagnostic and therapeutic approaches used to patients with clinical disease and carriers identified through familiar screening are also described. Progresses related especially to genetic screening and earlier intervention have permitted an improvement in the long-term outcome. However, treatment for disseminated disease is still ineffective.
多发性内分泌肿瘤(MEN)一词由Steiner等人于1968年提出,用于描述包括内分泌肿瘤组合在内的疾病。Wermer综合征设计为MEN 1,Sipple综合征为MEN 2。Sizemore等人(1974)完成了MEN 2类包括2个亚组:甲状腺髓样癌(MTC)、嗜铬细胞瘤、甲状旁腺疾病和外观正常的患者(MEN 2A),以及其他没有甲状旁腺疾病但有粘膜神经瘤和中胚层异常的患者(MEN 2B)。MTC通常是第一个被诊断出的肿瘤。MTC的诊断有几个意义:应该评估疾病程度,应该筛查嗜铬细胞瘤和甲状旁腺功能亢进症,并且应该通过直接分析RET原癌基因来确定MTC是散发性还是遗传性。在此,对MEN2的病理特征、遗传异常和临床特征进行了讨论。还介绍了用于临床疾病患者和通过常见筛查确定的携带者的诊断和治疗方法。特别是与基因筛查和早期干预相关的进展使长期结果得以改善。然而,对传播性疾病的治疗仍然无效。
{"title":"[Multiple endocrine neoplasia type 2].","authors":"A. Maia, J. Gross, Márcia Puñales","doi":"10.32388/0roru0","DOIUrl":"https://doi.org/10.32388/0roru0","url":null,"abstract":"The term multiple endocrine neoplasia (MEN) was introduced by Steiner et al. in 1968 to describe disorders that include a combination of endocrine tumors. The Wermer syndrome was designed as MEN 1 and the Sipple syndrome as MEN 2. Sizemore et al. (1974) completed that the MEN 2 category included 2 subgroups: patients with medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid disease and a normal appearance (MEN 2A) and other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B). MTC is usually the first tumor diagnosed. The diagnosis of MTC has several implications: disease extent should be evaluated, pheochromocytoma and hyperparathyroidism should be screened and whether the MTC is sporadic or hereditary should be determined by a direct analysis of the RET proto-oncogene. Here, the pathological characteristics, genetic abnormalities, and clinical features of MEN 2 are discussed. The diagnostic and therapeutic approaches used to patients with clinical disease and carriers identified through familiar screening are also described. Progresses related especially to genetic screening and earlier intervention have permitted an improvement in the long-term outcome. However, treatment for disseminated disease is still ineffective.","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44120973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 53
[Thyroid hormone resistance syndrome]. [甲状腺激素抵抗综合征]。
Pub Date : 2020-02-08 DOI: 10.32388/gopjpw
G. Carvalho, H. Ramos
{"title":"[Thyroid hormone resistance syndrome].","authors":"G. Carvalho, H. Ramos","doi":"10.32388/gopjpw","DOIUrl":"https://doi.org/10.32388/gopjpw","url":null,"abstract":"","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69631875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Large thyroid cyst in a patient with congenital hypothyroidism. 先天性甲状腺功能减退症患者的大甲状腺囊肿。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003287
Mahmoud Ali Kaykhaei, Zahra Heidari, Ahmad Mehrazin

Thyroid hormone biosynthetic defects are rare causes of congenital hypothyroidism. Although, initial presentations are usually diffuse goiter and hypothyroidism, subsequently they may develop thyroid nodules and or thyroid cancer. We describe a case of hypothyroidism due to dyshormonogenesis whose one of the previously solid nodules degenerates into a large cyst. A 22-year-old male was referred to our clinic for evaluation of enlarging thyroid nodule. Hypothyroidism was diagnosed in infancy, however due to poor compliance to treatment TSH values were elevated most of the times. When he was fifteen the first nodule was detected which was a solid cold nodule. Fine needle aspiration was in favor of benign follicular nodule. Seven years later we found a large multi nodular thyroid with a predominant large cyst corresponding to the previously detected solid nodule. 21cc straw colored fluid was aspirated. Cytology was reported as benign cystic nodule. The patient underwent thyroidectomy and pathology confirmed a benign thyroid cyst. Although underreported thyroid dyshormonogenesis may progress to cystic degeneration. Taking into account the risk of malignancy and eventually cyst formation, we recommend more frequent evaluation in the face of nodule formation in these patients.

甲状腺激素生物合成缺陷是先天性甲状腺功能减退症的罕见病因。虽然最初表现为弥漫性甲状腺肿和甲状腺功能减退,但随后可能发展为甲状腺结节和(或)甲状腺癌。我们描述了一个甲状腺功能减退症的情况下,由于激素产生障碍,其中一个以前的固体结节退化成一个大囊肿。一名22岁男性因甲状腺结节肿大而转诊至本诊所。婴儿期诊断为甲状腺功能减退症,但由于治疗依从性差,大多数时候TSH值升高。当他15岁时,第一个结节被发现,这是一个固体冷结节。细针穿刺有利于良性滤泡结节。七年后,我们发现了一个大的多结节性甲状腺,主要是一个大囊肿,与先前发现的实性结节相对应。抽吸21cc稻草色液体。细胞学报告为良性囊性结节。患者行甲状腺切除术,病理证实为良性甲状腺囊肿。虽然未被充分报道的甲状腺激素生成障碍可能发展为囊性变性。考虑到恶性肿瘤和最终囊肿形成的风险,我们建议在这些患者面对结节形成时更频繁地进行评估。
{"title":"Large thyroid cyst in a patient with congenital hypothyroidism.","authors":"Mahmoud Ali Kaykhaei,&nbsp;Zahra Heidari,&nbsp;Ahmad Mehrazin","doi":"10.1590/0004-2730000003287","DOIUrl":"https://doi.org/10.1590/0004-2730000003287","url":null,"abstract":"<p><p>Thyroid hormone biosynthetic defects are rare causes of congenital hypothyroidism. Although, initial presentations are usually diffuse goiter and hypothyroidism, subsequently they may develop thyroid nodules and or thyroid cancer. We describe a case of hypothyroidism due to dyshormonogenesis whose one of the previously solid nodules degenerates into a large cyst. A 22-year-old male was referred to our clinic for evaluation of enlarging thyroid nodule. Hypothyroidism was diagnosed in infancy, however due to poor compliance to treatment TSH values were elevated most of the times. When he was fifteen the first nodule was detected which was a solid cold nodule. Fine needle aspiration was in favor of benign follicular nodule. Seven years later we found a large multi nodular thyroid with a predominant large cyst corresponding to the previously detected solid nodule. 21cc straw colored fluid was aspirated. Cytology was reported as benign cystic nodule. The patient underwent thyroidectomy and pathology confirmed a benign thyroid cyst. Although underreported thyroid dyshormonogenesis may progress to cystic degeneration. Taking into account the risk of malignancy and eventually cyst formation, we recommend more frequent evaluation in the face of nodule formation in these patients.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Bariatric surgery--an update for the endocrinologist. 减肥手术,内分泌学家的最新进展。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003413
Marcio C Mancini

Obesity is a major public health problem, is associated with increased rates of mortality risk and of developing several comorbidities, and lessens life expectancy. Bariatric surgery is the most effective treatment for morbidly obese patients, reducing risk of developing new comorbidities, health care utilization and mortality. The establishment of centers of excellence with interdisciplinary staff in bariatric surgery has been reducing operative mortality in the course of time, improving surgical safety and quality. The endocrinologist is part of the interdisciplinary team. The aim of this review is to provide endocrinologists, physicians and health care providers crucial elements of good clinical practice in the management of morbidly obese bariatric surgical candidates. This information includes formal indications and contraindications for bariatric operations, description of usual bariatric and metabolic operations as well as endoscopic treatments, preoperative assessments including psychological, metabolic and cardiorespiratory evaluation and postoperative dietary staged meal progression and nutritional supplementation follow-up with micronutrient deficiencies monitoring, surgical complications, suspension of medications in type 2 diabetic patients, dumping syndrome and hypoglycemia.

肥胖是一个主要的公共卫生问题,与死亡风险增加和发生几种合并症有关,并缩短预期寿命。减肥手术是病态肥胖患者最有效的治疗方法,可降低发生新合并症、医疗保健利用和死亡率的风险。随着时间的推移,由跨学科人员组成的减肥手术卓越中心的建立,降低了手术死亡率,提高了手术安全性和质量。内分泌学家是这个跨学科团队的一员。本综述的目的是为内分泌学家、内科医生和卫生保健提供者提供良好临床实践管理病态肥胖减肥手术候选人的关键要素。这些信息包括减肥手术的正式适应症和禁忌症,常规减肥和代谢手术的描述以及内窥镜治疗,术前评估,包括心理、代谢和心肺评估,术后饮食分阶段膳食进展和营养补充随访,微量营养素缺乏监测,手术并发症,2型糖尿病患者停药,倾倒综合症和低血糖。
{"title":"Bariatric surgery--an update for the endocrinologist.","authors":"Marcio C Mancini","doi":"10.1590/0004-2730000003413","DOIUrl":"https://doi.org/10.1590/0004-2730000003413","url":null,"abstract":"<p><p>Obesity is a major public health problem, is associated with increased rates of mortality risk and of developing several comorbidities, and lessens life expectancy. Bariatric surgery is the most effective treatment for morbidly obese patients, reducing risk of developing new comorbidities, health care utilization and mortality. The establishment of centers of excellence with interdisciplinary staff in bariatric surgery has been reducing operative mortality in the course of time, improving surgical safety and quality. The endocrinologist is part of the interdisciplinary team. The aim of this review is to provide endocrinologists, physicians and health care providers crucial elements of good clinical practice in the management of morbidly obese bariatric surgical candidates. This information includes formal indications and contraindications for bariatric operations, description of usual bariatric and metabolic operations as well as endoscopic treatments, preoperative assessments including psychological, metabolic and cardiorespiratory evaluation and postoperative dietary staged meal progression and nutritional supplementation follow-up with micronutrient deficiencies monitoring, surgical complications, suspension of medications in type 2 diabetic patients, dumping syndrome and hypoglycemia.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003413","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33332414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Response to the letter: Angiotensin-II induced insulin resistance. 对信件的回应:血管紧张素ii诱导胰岛素抵抗。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003649
Marcos M Lima-Martínez, Gabriel López-Mendez, Rodolfo Odreman, José H Donis, Mariela Paoli
e have examined with attention the comments of the letter to the Editor in regards to our recently published article (1), and want to thank its authors for their interest in our work. Indeed, it has been demonstrated that, upon acting on the AT1 receptor, angio-tensin II activates matrix metalloproteases that release the epidermal growth factor (EGF), binding to its receptor promotes the activation of mammalian target of ra-pamycin (mTOR) and ribosomal S6 kinase-1, both of which inhibit phosphatidylino-sitol 3-kinase insulin signaling, thus favoring insulin resistance (2-4). Interestingly, some clinical studies have demonstrated that treatment with either angiotensin I-con -verter enzyme inhibitors (ACEI) or angiotensin II receptor antagonist (ARA) reduces the incidence of
{"title":"Response to the letter: Angiotensin-II induced insulin resistance.","authors":"Marcos M Lima-Martínez,&nbsp;Gabriel López-Mendez,&nbsp;Rodolfo Odreman,&nbsp;José H Donis,&nbsp;Mariela Paoli","doi":"10.1590/0004-2730000003649","DOIUrl":"https://doi.org/10.1590/0004-2730000003649","url":null,"abstract":"e have examined with attention the comments of the letter to the Editor in regards to our recently published article (1), and want to thank its authors for their interest in our work. Indeed, it has been demonstrated that, upon acting on the AT1 receptor, angio-tensin II activates matrix metalloproteases that release the epidermal growth factor (EGF), binding to its receptor promotes the activation of mammalian target of ra-pamycin (mTOR) and ribosomal S6 kinase-1, both of which inhibit phosphatidylino-sitol 3-kinase insulin signaling, thus favoring insulin resistance (2-4). Interestingly, some clinical studies have demonstrated that treatment with either angiotensin I-con -verter enzyme inhibitors (ACEI) or angiotensin II receptor antagonist (ARA) reduces the incidence of","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid nodules and thyroid cancer in Graves' disease. Graves病的甲状腺结节与甲状腺癌。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003569
Abbas Ali Tam, Cafer Kaya, Fevzi Balkan Mehmet Kılıç, Reyhan Ersoy, Bekir Çakır

Objective: The frequency of thyroid nodules accompanying Graves' disease and the risk of thyroid cancer in presence of accompanying nodules are controversial. The aim of this study was to evaluate the frequency of thyroid nodules and the risk of thyroid cancer in patients operated because of graves' disease.

Subjects and methods: Five hundred and twenty-six patients in whom thyroidectomy was performed because of Graves' disease between 2006 and 2013 were evaluated retrospectively. Patients who had received radioactive iodine treatment and external irradiation treatment in the neck region and who had had thyroid surgery previously were not included in the study.

Results: While accompanying thyroid nodule was present in 177 (33.6%) of 526 Graves' patients, thyroid nodule was absent in 349 (66.4%) patients. Forty-two (8%) patients had thyroid cancer. The rate of thyroid cancer was 5.4% (n = 19) in the Graves' patients who had no nodule, whereas it was 13% (n = 23) in the patients who had nodule. The risk of thyroid cancer increased significantly in presence of nodule (p = 0.003). Three patients had recurrence. No patient had distant metastasis. No patient died during the follow-up period.

Conclusions: Especially Graves' patients who have been decided to be followed up should be evaluated carefully during the follow-up in terms of thyroid cancer which may accompany.

目的:甲状腺结节伴格雷夫斯病的发生频率及伴结节伴发甲状腺癌的危险性存在争议。本研究的目的是评估因格雷夫斯病手术的患者甲状腺结节的频率和甲状腺癌的风险。对象和方法:对2006 - 2013年间526例因Graves病行甲状腺切除术的患者进行回顾性分析。在颈部接受过放射性碘治疗和外照射治疗的患者以及之前做过甲状腺手术的患者不在研究范围内。结果:526例Graves患者中伴发甲状腺结节177例(33.6%),未见甲状腺结节349例(66.4%)。42例(8%)患者患有甲状腺癌。无结节的Graves患者甲状腺癌发生率为5.4% (n = 19),而有结节的患者甲状腺癌发生率为13% (n = 23)。存在结节时甲状腺癌的发生风险显著增加(p = 0.003)。3例复发。无远处转移。随访期间无患者死亡。结论:特别是已确定随访的Graves患者,在随访时应仔细评估其是否伴有甲状腺癌。
{"title":"Thyroid nodules and thyroid cancer in Graves' disease.","authors":"Abbas Ali Tam,&nbsp;Cafer Kaya,&nbsp;Fevzi Balkan Mehmet Kılıç,&nbsp;Reyhan Ersoy,&nbsp;Bekir Çakır","doi":"10.1590/0004-2730000003569","DOIUrl":"https://doi.org/10.1590/0004-2730000003569","url":null,"abstract":"<p><strong>Objective: </strong>The frequency of thyroid nodules accompanying Graves' disease and the risk of thyroid cancer in presence of accompanying nodules are controversial. The aim of this study was to evaluate the frequency of thyroid nodules and the risk of thyroid cancer in patients operated because of graves' disease.</p><p><strong>Subjects and methods: </strong>Five hundred and twenty-six patients in whom thyroidectomy was performed because of Graves' disease between 2006 and 2013 were evaluated retrospectively. Patients who had received radioactive iodine treatment and external irradiation treatment in the neck region and who had had thyroid surgery previously were not included in the study.</p><p><strong>Results: </strong>While accompanying thyroid nodule was present in 177 (33.6%) of 526 Graves' patients, thyroid nodule was absent in 349 (66.4%) patients. Forty-two (8%) patients had thyroid cancer. The rate of thyroid cancer was 5.4% (n = 19) in the Graves' patients who had no nodule, whereas it was 13% (n = 23) in the patients who had nodule. The risk of thyroid cancer increased significantly in presence of nodule (p = 0.003). Three patients had recurrence. No patient had distant metastasis. No patient died during the follow-up period.</p><p><strong>Conclusions: </strong>Especially Graves' patients who have been decided to be followed up should be evaluated carefully during the follow-up in terms of thyroid cancer which may accompany.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
The TCF7L2 rs7903146 (C/T) polymorphism is associated with risk to type 2 diabetes mellitus in Southern-Brazil. TCF7L2 rs7903146 (C/T)多态性与巴西南部2型糖尿病的风险相关。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003510
Taís S Assmann, Guilherme C K Duarte, Jakeline Rheinheimer, Lavínia A Cruz, Luís H Canani, Daisy Crispim

Objective: The aim of this study was to investigate the association between the rs7903146 (C/T) polymorphism in the TCF7L2 gene and type 2 diabetes mellitus, in a Southern-Brazilian population.

Materials and methods: The TCF7L2 rs7903146 polymorphism was genotyped in 953 type 2 diabetic patients and 535 non-diabetic subjects. All subjects were white. The polymorphism was genotyped by Real-Time PCR using TaqMan MGB probes (Life Technologies). Odds ratios (OR) and 95% confidence intervals (CI) were calculated for additive, recessive and dominant inheritance models.

Results: Genotype and allele frequencies of the rs7903146 polymorphism differed significantly between type 2 diabetic patients and non-diabetic subjects (P = 0.001 and P = 0.0001, respectively). The frequency of the minor allele was 38% in type 2 diabetes group and 31% in non-diabetic subjects, and this allele was significantly associated with type 2 diabetes risk (OR = 1.42, 95% CI 1.15 - 1.76 for the dominant model of inheritance). Moreover, the T/T genotype was associated with a higher risk for type 2 diabetes (OR = 1.83, 95% CI 1.3-2.5) than the presence of only one copy of the T allele (OR = 1.31, 95% CI 1.1-1.6). Both results were adjusted for age and gender.

Conclusions: Our results confirm the association between the TCF7L2 rs7903146 polymorphism and increase risk for type 2 diabetes in Southern-Brazil.

目的:本研究的目的是调查巴西南部人群中TCF7L2基因rs7903146 (C/T)多态性与2型糖尿病之间的关系。材料与方法:对953例2型糖尿病患者和535例非糖尿病患者的TCF7L2 rs7903146多态性进行基因分型。所有的实验对象都是白人。采用TaqMan MGB探针(Life Technologies)进行实时荧光定量PCR分型。计算加性、隐性和显性遗传模型的优势比(OR)和95%置信区间(CI)。结果:2型糖尿病患者与非糖尿病患者rs7903146多态性基因型和等位基因频率差异有统计学意义(P = 0.001和P = 0.0001)。次要等位基因在2型糖尿病组的频率为38%,在非糖尿病组的频率为31%,该等位基因与2型糖尿病风险显著相关(显性遗传模型OR = 1.42, 95% CI 1.15 - 1.76)。此外,T/T基因型与仅存在一个T等位基因拷贝(OR = 1.31, 95% CI 1.1-1.6)相比,患2型糖尿病的风险更高(OR = 1.83, 95% CI 1.3-2.5)。这两个结果都根据年龄和性别进行了调整。结论:我们的研究结果证实了TCF7L2 rs7903146多态性与巴西南部2型糖尿病风险增加之间的关联。
{"title":"The TCF7L2 rs7903146 (C/T) polymorphism is associated with risk to type 2 diabetes mellitus in Southern-Brazil.","authors":"Taís S Assmann,&nbsp;Guilherme C K Duarte,&nbsp;Jakeline Rheinheimer,&nbsp;Lavínia A Cruz,&nbsp;Luís H Canani,&nbsp;Daisy Crispim","doi":"10.1590/0004-2730000003510","DOIUrl":"https://doi.org/10.1590/0004-2730000003510","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate the association between the rs7903146 (C/T) polymorphism in the TCF7L2 gene and type 2 diabetes mellitus, in a Southern-Brazilian population.</p><p><strong>Materials and methods: </strong>The TCF7L2 rs7903146 polymorphism was genotyped in 953 type 2 diabetic patients and 535 non-diabetic subjects. All subjects were white. The polymorphism was genotyped by Real-Time PCR using TaqMan MGB probes (Life Technologies). Odds ratios (OR) and 95% confidence intervals (CI) were calculated for additive, recessive and dominant inheritance models.</p><p><strong>Results: </strong>Genotype and allele frequencies of the rs7903146 polymorphism differed significantly between type 2 diabetic patients and non-diabetic subjects (P = 0.001 and P = 0.0001, respectively). The frequency of the minor allele was 38% in type 2 diabetes group and 31% in non-diabetic subjects, and this allele was significantly associated with type 2 diabetes risk (OR = 1.42, 95% CI 1.15 - 1.76 for the dominant model of inheritance). Moreover, the T/T genotype was associated with a higher risk for type 2 diabetes (OR = 1.83, 95% CI 1.3-2.5) than the presence of only one copy of the T allele (OR = 1.31, 95% CI 1.1-1.6). Both results were adjusted for age and gender.</p><p><strong>Conclusions: </strong>Our results confirm the association between the TCF7L2 rs7903146 polymorphism and increase risk for type 2 diabetes in Southern-Brazil.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003510","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
An international survey of screening and management of hypothyroidism during pregnancy in Latin America. 拉丁美洲妊娠期间甲状腺功能减退症的筛查和管理的国际调查。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003382
Mateus Fernandes da Silva Medeiros, Taise Lima de Oliveira Cerqueira, Joaquim Custódio Silva Junior, Magali Teresopolis Reis Amaral, Bijay Vaidya, Kris Gustave Poppe, Gisah Amaral de Carvalho, Silvia Gutierrez, Graciela Alcaraz, Marcos Abalovich, Helton Estrela Ramos

Objective: To determine how endocrinologists in Latin America deal with clinical case scenarios related to hypothyroidism and pregnancy.

Materials and methods: In January 2013, we sent an electronic questionnaire on current practice relating to management of hypothyroidism in pregnancy to 856 members of the Latin American Thyroid Society (LATS) who manage pregnant patients with thyroid disease. Subsequently, we have analyzed responses from physician members.

Results: Two hundred and ninety-three responders represent clinicians from 13 countries. All were directly involved in the management of maternal hypothyroidism and 90.7% were endocrinologists. The recommendation of a starting dose of L-thyoxine for a woman diagnosed with overt hypothyroidism in pregnancy, preconception management of euthyroid women with known thyroid autoimmunity and approach related to ovarian hyperstimulation in women with thyroid peroxidase antibodies were widely variable. For women with known hypothyroidism, 34.6% of responders would increase L-thyroxine dose by 30-50% as soon as pregnancy is confirmed. With regard to screening, 42.7% of responders perform universal evaluation and 70% recommend TSH < 2.5 mUI/L in the first trimester and TSH < 3 mUI/L in the second and third trimester as target results in known hypothyroid pregnant women.

Conclusion: Deficiencies in diagnosis and management of hypothyroidism during pregnancy were observed in our survey, highlighting the need for improvement of specialist education and quality of care offered to patients with thyroid disease during pregnancy in Latin America.

目的:确定拉丁美洲内分泌学家如何处理与甲状腺功能减退和妊娠有关的临床病例。材料和方法:2013年1月,我们向856名管理妊娠甲状腺疾病患者的拉丁美洲甲状腺协会(LATS)成员发送了一份关于妊娠甲状腺功能减退管理现状的电子问卷。随后,我们分析了来自医师会员的反馈。结果:293名应答者代表来自13个国家的临床医生。其中90.7%为内分泌科医生,直接参与产妇甲状腺功能减退症的治疗。对于诊断为妊娠期明显甲状腺功能减退的妇女,对已知甲状腺自身免疫的甲状腺功能正常妇女的孕前处理,以及对甲状腺过氧化物酶抗体妇女卵巢过度刺激的方法的推荐起始剂量有很大的不同。对于已知甲状腺功能减退的妇女,34.6%的应答者在确认怀孕后立即增加30-50%的l -甲状腺素剂量。在筛查方面,42.7%的应答者进行了普遍评估,70%的应答者推荐妊娠早期TSH < 2.5 mUI/L,妊娠中期和晚期TSH < 3 mUI/L作为已知甲状腺功能低下孕妇的目标结果。结论:在我们的调查中观察到妊娠期间甲状腺功能减退的诊断和管理不足,突出了拉丁美洲需要改善专科教育和为妊娠期间甲状腺疾病患者提供的护理质量。
{"title":"An international survey of screening and management of hypothyroidism during pregnancy in Latin America.","authors":"Mateus Fernandes da Silva Medeiros,&nbsp;Taise Lima de Oliveira Cerqueira,&nbsp;Joaquim Custódio Silva Junior,&nbsp;Magali Teresopolis Reis Amaral,&nbsp;Bijay Vaidya,&nbsp;Kris Gustave Poppe,&nbsp;Gisah Amaral de Carvalho,&nbsp;Silvia Gutierrez,&nbsp;Graciela Alcaraz,&nbsp;Marcos Abalovich,&nbsp;Helton Estrela Ramos","doi":"10.1590/0004-2730000003382","DOIUrl":"https://doi.org/10.1590/0004-2730000003382","url":null,"abstract":"<p><strong>Objective: </strong>To determine how endocrinologists in Latin America deal with clinical case scenarios related to hypothyroidism and pregnancy.</p><p><strong>Materials and methods: </strong>In January 2013, we sent an electronic questionnaire on current practice relating to management of hypothyroidism in pregnancy to 856 members of the Latin American Thyroid Society (LATS) who manage pregnant patients with thyroid disease. Subsequently, we have analyzed responses from physician members.</p><p><strong>Results: </strong>Two hundred and ninety-three responders represent clinicians from 13 countries. All were directly involved in the management of maternal hypothyroidism and 90.7% were endocrinologists. The recommendation of a starting dose of L-thyoxine for a woman diagnosed with overt hypothyroidism in pregnancy, preconception management of euthyroid women with known thyroid autoimmunity and approach related to ovarian hyperstimulation in women with thyroid peroxidase antibodies were widely variable. For women with known hypothyroidism, 34.6% of responders would increase L-thyroxine dose by 30-50% as soon as pregnancy is confirmed. With regard to screening, 42.7% of responders perform universal evaluation and 70% recommend TSH < 2.5 mUI/L in the first trimester and TSH < 3 mUI/L in the second and third trimester as target results in known hypothyroid pregnant women.</p><p><strong>Conclusion: </strong>Deficiencies in diagnosis and management of hypothyroidism during pregnancy were observed in our survey, highlighting the need for improvement of specialist education and quality of care offered to patients with thyroid disease during pregnancy in Latin America.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003382","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33332417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
A case of thyroid hormone resistance: a rare mutation. 一例甲状腺激素抵抗:罕见的突变。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003297
Ana Pires Gonçalves, José Maria Aragüés, Ema Nobre, Ana Paula Barbosa, Mario Mascarenhas

Reduced sensitivity to thyroid hormones (RSTH) is a rare disease that affects about 3,000 individuals, belonging to about 1,000 families. It results from reduced intracellular action of thyroid hormones (TH) genetically determined and manifests as persistent hyperthyroxinemia with non-suppressed thyroid-stimulating hormone (TSH). We describe a 67-years old, Caucasian woman, with past history of subtotal thyroidectomy due to diffuse goiter, who presents with a recurrence of goiter. Although she is clinically euthyroid, laboratory evaluation shows persistent hyperthyroxinemia with non-suppressed TSH. Response to thyrotropin releasing hormone (TRH) test was normal and TSH concentrations were not suppressed during oral administration of suprafisiologic doses of levothyroxine (L-T4). Peripheral blood DNA was extracted from the patient and a mutation was found localized in cluster one, at codon 346 of the ligand binding domain of the THRB gene. The patient's son underwent thyroid function testing (TFT) and genetic study, both negative, suggesting a sporadic mutation. RSTH should be considered in all hyperthyroxinemic patients who are clinically euthyroid. Mutations interfering with three major steps required for TH action on target tissues have been, so far, identified (TR-β, TR-α, MCT8, SPB2). Each mutation is associated with a distinctive syndrome. Goal of management is to maintain a normal serum TSH level and a eumetabolic state and offer appropriate genetic counselling and prenatal diagnosis. Inappropriate treatment of eumetabolic patients results in hypothyroidism and need for TH replacement.

甲状腺激素敏感性降低(RSTH)是一种罕见的疾病,影响约3000人,属于约1000个家庭。它是由基因决定的甲状腺激素(TH)细胞内作用减少引起的,表现为持续的高甲状腺素血症伴非抑制性促甲状腺激素(TSH)。我们描述了一位67岁的白人女性,既往因弥漫性甲状腺肿而行甲状腺次全切除术,现甲状腺肿复发。虽然她的临床甲状腺功能正常,但实验室评估显示持续的高甲亢血症伴非抑制性TSH。对促甲状腺激素释放激素(TRH)试验的反应正常,口服超剂量左旋甲状腺素(L-T4)未抑制TSH浓度。提取患者外周血DNA,发现突变位于THRB基因配体结合域密码子346的第1簇。患者的儿子进行了甲状腺功能测试(TFT)和基因研究,均为阴性,提示有散发性突变。所有临床甲状腺功能正常的甲亢患者均应考虑RSTH。到目前为止,已经确定了干扰TH作用于靶组织所需的三个主要步骤的突变(TR-β, TR-α, MCT8, SPB2)。每种突变都与一种独特的综合征有关。管理的目标是维持正常的血清TSH水平和代谢状态,并提供适当的遗传咨询和产前诊断。非代谢患者治疗不当导致甲状腺功能减退,需要甲状腺激素替代。
{"title":"A case of thyroid hormone resistance: a rare mutation.","authors":"Ana Pires Gonçalves,&nbsp;José Maria Aragüés,&nbsp;Ema Nobre,&nbsp;Ana Paula Barbosa,&nbsp;Mario Mascarenhas","doi":"10.1590/0004-2730000003297","DOIUrl":"https://doi.org/10.1590/0004-2730000003297","url":null,"abstract":"<p><p>Reduced sensitivity to thyroid hormones (RSTH) is a rare disease that affects about 3,000 individuals, belonging to about 1,000 families. It results from reduced intracellular action of thyroid hormones (TH) genetically determined and manifests as persistent hyperthyroxinemia with non-suppressed thyroid-stimulating hormone (TSH). We describe a 67-years old, Caucasian woman, with past history of subtotal thyroidectomy due to diffuse goiter, who presents with a recurrence of goiter. Although she is clinically euthyroid, laboratory evaluation shows persistent hyperthyroxinemia with non-suppressed TSH. Response to thyrotropin releasing hormone (TRH) test was normal and TSH concentrations were not suppressed during oral administration of suprafisiologic doses of levothyroxine (L-T4). Peripheral blood DNA was extracted from the patient and a mutation was found localized in cluster one, at codon 346 of the ligand binding domain of the THRB gene. The patient's son underwent thyroid function testing (TFT) and genetic study, both negative, suggesting a sporadic mutation. RSTH should be considered in all hyperthyroxinemic patients who are clinically euthyroid. Mutations interfering with three major steps required for TH action on target tissues have been, so far, identified (TR-β, TR-α, MCT8, SPB2). Each mutation is associated with a distinctive syndrome. Goal of management is to maintain a normal serum TSH level and a eumetabolic state and offer appropriate genetic counselling and prenatal diagnosis. Inappropriate treatment of eumetabolic patients results in hypothyroidism and need for TH replacement. </p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003297","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Red cell distribution width in subclinical hypothyroidism. 亚临床甲状腺功能减退的红细胞分布宽度。
Pub Date : 2014-12-01 DOI: 10.1590/0004-2730000003452
Sevket Balta, Mustafa Aparci, Cengiz Ozturk, Sait Demirkol, Turgay Celik, Atila Iyisoy
e have read the article “The value of red blood cell distribution width (RDW) in subclinical hypothyroidism” by Hea Min Yu and cols. (1). They aimed to investigate the relationship between the subclinical hypothyroidism and RDW levels in a healthy population. They concluded that RDW levels were correlated with euthyroid and subclinical thyroid status. This study gives important information on this clinically relevant condition. Thanks to the authors for their contribution. We think that some points should be discussed. Some markers have been found to be associated with early and late complications in many conditions. Inflammatory cytokines, high-sensitivity C-reactive protein (CRP), natriuretic peptides, neurohormones have recently established to be useful markers for diagnosis and prognosis in many diseases. However, these markers are very expensive and are not easily used in clinical practice. Elevated RDW is a measure of the variabi-lity in size of circulating erythrocytes and is expressed as the coefficient of variation of the erythrocyte volume. As several routine haematology instruments can analyse erythrocyte volume, RDW is available in most clinical settings. The ready availability of this parameter without additional cost may encourage its wider use in clinical pra-ctice. Several studies have reported that elevated RDW levels are associated with poor prognosis in the setting of atherosclerosis, heart failure, stroke, peripheral arterial dis -ease, older age (2). However, RDW may also reflect ethnicity, neurohumoral activa-tion, renal dysfunction, hepatic dysfunction, nutritional deficiencies (i.e. iron, vitamin B
{"title":"Red cell distribution width in subclinical hypothyroidism.","authors":"Sevket Balta,&nbsp;Mustafa Aparci,&nbsp;Cengiz Ozturk,&nbsp;Sait Demirkol,&nbsp;Turgay Celik,&nbsp;Atila Iyisoy","doi":"10.1590/0004-2730000003452","DOIUrl":"https://doi.org/10.1590/0004-2730000003452","url":null,"abstract":"e have read the article “The value of red blood cell distribution width (RDW) in subclinical hypothyroidism” by Hea Min Yu and cols. (1). They aimed to investigate the relationship between the subclinical hypothyroidism and RDW levels in a healthy population. They concluded that RDW levels were correlated with euthyroid and subclinical thyroid status. This study gives important information on this clinically relevant condition. Thanks to the authors for their contribution. We think that some points should be discussed. Some markers have been found to be associated with early and late complications in many conditions. Inflammatory cytokines, high-sensitivity C-reactive protein (CRP), natriuretic peptides, neurohormones have recently established to be useful markers for diagnosis and prognosis in many diseases. However, these markers are very expensive and are not easily used in clinical practice. Elevated RDW is a measure of the variabi-lity in size of circulating erythrocytes and is expressed as the coefficient of variation of the erythrocyte volume. As several routine haematology instruments can analyse erythrocyte volume, RDW is available in most clinical settings. The ready availability of this parameter without additional cost may encourage its wider use in clinical pra-ctice. Several studies have reported that elevated RDW levels are associated with poor prognosis in the setting of atherosclerosis, heart failure, stroke, peripheral arterial dis -ease, older age (2). However, RDW may also reflect ethnicity, neurohumoral activa-tion, renal dysfunction, hepatic dysfunction, nutritional deficiencies (i.e. iron, vitamin B","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arquivos brasileiros de endocrinologia e metabologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1